Agios' posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348, two small molecule activators of pyruvate kinase R

Read the full 310 word article

User Sign In